Prostate News and Research

RSS

Chronic viruses found living in prostate tumors

According to Dr. Ila R. Singh, an associate professor of pathology at the University of Utah, "for the first time we have analyzed prostate cancer and normal prostate tissue and found cancers are much more likely to have [the XMRV virus] ... It was also more likely to be present in more aggressive tumors," Singh said. "We found it in 20 percent of the least aggressive tumors and over 45 percent of the most aggressive tumors."

21 Sep 2009

Swedish researcher to receive Fernström Foundation's Nordic Prize

Internationally renowned Swedish researcher Professor Jan-Åke Gustafsson, from KI and the University of Houston, is this year's recipient of the Fernström Foundation's Nordic Prize. The prize, which is worth SEK 1 million, is one of Scandinavia's most prestigious medical prizes.

21 Sep 2009

Results of Phase 1 study of Oral AEZS-112 announced by Aeterna Zentaris

Æterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) ("the Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the completion of a Phase 1 study of its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.

21 Sep 2009

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number: 20LBA).

21 Sep 2009

Four single-letter variations in SNPs increse prostate cancer risk

deCODE genetics (Nasdaq: DCGN) today announced that a team of its scientists and academic colleagues from Finland, Spain, the Netherlands and the United States have today published the discovery of four novel single-letter variations in the sequence of the human genome (SNPs) conferring increased risk of prostate cancer.

21 Sep 2009

Health Discovery Corporation appoints new COO

Health Discovery Corporation, a personalized medicine company specializing in molecular diagnostics including gene-based testing, as well as computer assisted diagnostics in digital pathology and radiology, announced that former Deputy FDA Commissioner John A. Norris has been appointed as Chief Operating Officer (COO) of the Company.

19 Sep 2009

Prostate cancer more prevalent in African-American men

A new guide, Straight Talk for African-American Men and their Families, is now available from the Prostate Cancer Foundation (PCF). It was produced in alliance with Charlie Wilson, famed R&B singer and recent prostate cancer survivor.

19 Sep 2009

Drug carrier that cuts off blood supply to tumors

To that end, Dr. Ronit Satchi-Fainaro of Tel Aviv University's Department of Physiology and Pharmacology, Sackler School of Medicine, and her team of researchers have developed a new drug carrier to deliver compounds straight to the tumor.

18 Sep 2009

CI Index of ten leading cancer immunotherapy stocks increase by 58% in two months

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 58% in its first two months of reporting. CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (IMUC.OB) under the leadership of CEO Manish Singh, Ph. D.

17 Sep 2009

CHUM installs CyberKnife system for effective cancer treatment in Canada

Accuray Incorporated, a global leader in the field of radiosurgery today announced that Centre Hospitalier de l'Universite de Montreal (CHUM) has installed a CyberKnife(R) Robotic Radiosurgery System at Hopital Notre-Dame du CHUM, in Montreal, Canada.

17 Sep 2009

Mayo Clinic Health Letter discusses kidney stone treatment options

Ordinary, loud snoring doesn't seem to be harmful, according to the September issue of Mayo Clinic Health Letter. But snorers still may want to seek treatment to stop snoring, reduce embarrassment and improve sleep for themselves and their bed partner.

17 Sep 2009

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

17 Sep 2009

Quest PharmaTech reports second quarter fiscal 2009 results

Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced fiscal second quarter results for the period ended July 31, 2009.

17 Sep 2009

ColoMarker assay achieves 100 percent detection rate for colon cancers

Marking a major milestone in the early detection and management of colon cancer, EDP Biotech Corporation (EDP), a developer of immunodiagnostic tests for humans and animals, announced today that its ColoMarker assay achieved 100 percent detection rate for colon cancers presented at stages I through III in pre-clinical trials.

17 Sep 2009

Educational events for physicians who diagnose and treat prostate cancer

iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announces a series of educational events designed for radiologists, urologists, oncologists, radiation oncologists, surgeons, technologists and other referring physicians who diagnose and treat patients with prostate cancer.

17 Sep 2009

Diagnocure reports third-quarter fiscal 2009 results

DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced revenue of $396,468 and a net loss of $4,034,364 or $0.09 per share for the third quarter ending July 31, 2009.

17 Sep 2009

Amgen to present its four Phase 3 clinical trial results

Amgen today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.

16 Sep 2009

Cryosurgery: Primary treatment option for prostate cancer

After years of innovation and intensive research, a team of Binghamton University (BU) researchers working with Cell Preservation Services, Inc., Owego, NY has broken extraordinary new ground in the recognition of cryosurgery as a primary treatment option for prostate cancer.

16 Sep 2009

PCEC to provide free prostate cancer screenings

This September, the Prostate Conditions Education Council reminds men to set aside 10 minutes to take lifesaving measures. In just 10 minutes, the same amount of time it takes to shave their faces, men can be screened for prostate cancer, the second leading cause of death among American men. For one week this month the Prostate Conditions Education Council (PCEC) will be coordinating Prostate Cancer Awareness Week (PCAW), which provides free or low-cost screenings to thousands of men across the United States.

16 Sep 2009

Premion commences cancer treatment with Varian's RapidArc radiotherapy technology

Cancer patients in Australia have gained access to advanced RapidArc(R) radiotherapy treatments from Varian Medical Systems (NYSE: VAR) with its introduction by the leading radiation oncology provider in Queensland. Premion, which operates five cancer centers in Queensland, has treated more than a dozen prostate cancer patients to date with this fast, precise and efficient technique at its Chermside treatment center in Brisbane.

16 Sep 2009